Ascentage Pharma Group International Co., Ltd. (6855) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Wuxi Biologics (Cayman), Inc.

3SBio, Inc.

Alphamab Oncology

CSPC Pharmaceutical Group Ltd.

Sirnaomics Ltd.

AIM Vaccine Co., Ltd.

Zai Lab Ltd.

Laekna, Inc.

Beijing Lüzhu Biotechnology Co., Ltd.

Ascentage Pharma Group International Co., Ltd.

Genscript Biotech Corp.

Why is Ascentage Pharma Group International Co., Ltd. ?

Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 0%

Poor long term growth as Operating profit has grown by an annual rate -18.51% of over the last 5 years
High Debt Company with a Debt to Equity ratio (avg) at times
NET SALES(Q) At HKD 251.03 MM has Fallen at -71.88%
DEBTORS TURNOVER RATIO(HY) Lowest at 0.95 times
PRE-TAX PROFIT(Q) Lowest at HKD -660.77 MM

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 13.40%, its profits have risen by 56.9%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Ascentage Pharma Group International Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Ascentage Pharma Group International Co., Ltd.

13.4%

2.35

63.83%

Hang Seng Hong Kong

8.25%

0.41

19.93%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

91.26%

EBIT Growth (5y)

-18.51%

EBIT to Interest (avg)

-39.31

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

1.57

Sales to Capital Employed (avg)

0.15

Tax Ratio

2.64%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

103.00

EV to EBIT

-71.51

EV to EBITDA

-94.80

EV to Capital Employed

40.63

EV to Sales

27.66

PEG Ratio

Dividend Yield

ROCE (Latest)

-56.81%

ROE (Latest)

-156.72%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company

OPERATING CASH FLOW(Y)

Highest at HKD -1,076.06 MM

RAW MATERIAL COST(Y)

Fallen by -21.27% (YoY

CASH AND EQV(HY)

Highest at HKD 1,820.17 MM

DEBT-EQUITY RATIO (HY)

Lowest at 8.21 %

-11What is not working for the Company

NET SALES(Q)

At HKD 251.03 MM has Fallen at -71.88%

DEBTORS TURNOVER RATIO(HY)

Lowest at 0.95 times

PRE-TAX PROFIT(Q)

Lowest at HKD -660.77 MM

NET PROFIT(Q)

Lowest at HKD -666.63 MM

Here's what is working for Ascentage Pharma Group International Co., Ltd.

Operating Cash Flow

Highest at HKD -1,076.06 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (HKD MM)

Cash and Eqv

Highest at HKD 1,820.17 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio

Lowest at 8.21 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by -21.27% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Ascentage Pharma Group International Co., Ltd.

Pre-Tax Profit

At HKD -660.77 MM has Fallen at -472.63%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (HKD MM)

Net Profit

At HKD -666.63 MM has Fallen at -478.58%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (HKD MM)

Net Sales

At HKD 251.03 MM has Fallen at -71.88%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very negative

Net Sales (HKD MM)

Pre-Tax Profit

Lowest at HKD -660.77 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (HKD MM)

Net Profit

Lowest at HKD -666.63 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (HKD MM)

Debtors Turnover Ratio

Lowest at 0.95 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio